Two Sigma Investments LP Has $2.43 Million Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Two Sigma Investments LP decreased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 33.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,398 shares of the medical instruments supplier's stock after selling 13,279 shares during the period. Two Sigma Investments LP owned 0.12% of LeMaitre Vascular worth $2,432,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its position in LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC lifted its holdings in LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 117 shares during the period. KBC Group NV grew its stake in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank grew its position in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $150,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $97.83.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George W. Lemaitre sold 18,733 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the sale, the chief executive officer now owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,009 shares of company stock worth $8,721,836 over the last 90 days. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $0.31 on Wednesday, hitting $82.55. The company's stock had a trading volume of 101,781 shares, compared to its average volume of 168,743. The stock's 50-day moving average is $83.75 and its two-hundred day moving average is $91.44. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 45.11, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's revenue was up 12.0% compared to the same quarter last year. During the same period last year, the firm earned $0.44 EPS. Equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 40.40%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.